| Old Articles: <Older 5051-5060 Newer> |
|---|
 |
The Motley Fool
August 25, 2008
Brian Lawler |
King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market.   |
The Motley Fool
August 25, 2008
Brian Lawler |
Amgen Gets Its FDA Response Amgen investors can finally breathe a little sigh of relief after the biopharma giant announces that the Food and Drug Administration has finally approved its blood disorder drug. |
The Motley Fool
August 22, 2008
Brian Orelli |
Abbott Tries a Crash Diet The health-care conglomerate is cutting jobs in its diagnostic testing division. |
The Motley Fool
August 22, 2008
Brian Orelli |
Don't Worry About Vytorin's Cancer Risk While it doesn't seem that the investigations are likely to turn up anything, investors should at least keep up with the amount of news surrounding the Vytorin probe. |
The Motley Fool
August 21, 2008
Brian Orelli |
Johnson & Johnson Gets Rejected The FDA rejects Johnson & Johnson's bid to expand the label of its antibiotic. |
The Motley Fool
August 21, 2008
Brian Lawler |
Regeneron's Results Clearing Up The drugmaker presents new data on a compelling candidate for macular degeneration treatment. |
The Motley Fool
August 21, 2008
Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |
The Motley Fool
August 20, 2008
Brian Orelli |
A Moooving Acquisition Eli Lilly buys Monsanto's cow hormone business. |
The Motley Fool
August 20, 2008
Brian Orelli |
Medtronic Muddles Through The medical device maker manages double-digit growth in a tough market. |
The Motley Fool
August 19, 2008
Brian Orelli |
Too Much Punishment for Amylin Several more pancreatitis cases cause Amylin Pharmaceuticals' investors to panic. |
| <Older 5051-5060 Newer> Return to current articles. |
